Pharmacokinetics and Pharmacodynamics Lecture Review

Pharmacokinetics (movement of drugs through the body)

  • Kinetics comes from kinesis = motion; pharmacokinetics = how drugs move through the body and what happens to them on that journey.

  • Four basic principles of pharmacokinetics:

    • Absorption

    • Distribution

    • Metabolism

    • Excretion

  • These four processes describe the journey from administration to exit; the lectures return to this framework between sections.

Absorption
  • Definition: movement of a drug from the site of administration into the bloodstream.

  • Key questions: how fast effects begin (rate of absorption) and how strong the effects are (extent of absorption).

  • Why absorption matters: determines site-of-action drug concentration, helps estimate maximum effect, and informs safety/efficacy.

  • Drug entry into cells and crossing the cell membrane:

    • Cell membrane barrier is a phospholipid bilayer; many drugs cross by direct penetration if lipophilic.

    • Three main routes across the membrane:

    • Direct penetration of the membrane (primary route for many drugs).

    • Transport systems (may require energy, e.g., ATP; can be selective).

    • Channels/pores (used by very small ions; most drugs are too large).

    • Lipid solubility and the principle of ā€œlike dissolves likeā€: lipophilic (lipid-soluble) drugs cross membranes more easily; water-soluble drugs cross less easily.

  • Ionization and pH effects:

    • Drugs are acids or bases. Acids are proton donors; bases are proton acceptors.

    • Ionization affects absorption location and efficiency because ionized forms cross membranes poorly.

    • Example: aspirin (acetylsalicylic acid) is an acid; in the stomach (acidic pH) it remains largely non-ionized and is absorbed; in the small intestine (more basic environment) aspirin ionizes and absorption decreases.

    • Henderson–Hasselbalch intuition (brief): for acids, pH = pKa + log([A^-]/[HA]); for bases, pH = pKa + log([B]/[BH^+]). Ionization state shifts with pH and affects absorption.

  • Absorption factors that enhance absorption (rate and extent):

    • Rate of dissolution

    • Surface area at the absorption site

    • Blood flow to the site

    • Lipid solubility

    • pH partitioning (the ionization state in local pH)

  • Absorption factors: practice question note

    • Drug absorption is enhanced by dissolution rate, surface area, blood flow, and lipid solubility, and by favorable pH partitioning; absorption is not enhanced when ionization favors ionized forms (ionized forms absorb poorly).

  • Routes of administration (two broad categories):

    • Enteral (GI tract): oral, NG tubes, G-tubes, etc.

    • Parenteral (outside GI tract): injections (IV, IM, subcutaneous, etc.).

  • Intravenous (IV) administration:

    • Fastest route; absorption is essentially instantaneous and complete (no barriers to absorption).

    • Advantages:

    • Rapid onset

    • Precise control of the drug amount entering the systemic circulation

    • Can dilute irritating drugs by giving with fluids

    • Disadvantages/risks:

    • High cost of fluids and equipment; requires specialized training

    • Irreversible once administered (cannot ā€œpull backā€ into syringe)

    • Risk of fluid overload, infection, embolism

    • Concentration and dosage may differ from oral forms (e.g., morphine IV vs oral)

  • Intramuscular (IM) and Subcutaneous (SC) administration:

    • Absorption depends on blood flow and tissue access; it can be rapid or slow

    • Advantages:

    • Good for drugs that do not cross membranes easily

    • Depot preparations allow slow, extended absorption (months/weeks)

    • Disadvantages:

    • Less convenient; discomfort; potential tissue injury or nerve damage

  • Oral (per os) administration:

    • Absorption occurs in the GI tract after dissolution and barrier crossing into the bloodstream

    • Advantages:

    • Easy, convenient, lower cost, reversible

    • Disadvantages:

    • High variability in absorption between individuals

    • May be inactivated by stomach acid or digestive enzymes; gastric pH variations affect absorption

    • Local GI irritation possible; may require enteric coatings to control dissolution and rate

    • Factors affecting oral absorption (recap):

    • Drug dissolution rate and formulation (e.g., coatings)

    • Gastric emptying time and intestinal transit

    • Presence of food or other drugs (food effects)

  • Practical teaching point:

    • As a nurse, you cannot arbitrarily change the route of administration; route selection is a decision in the clinical plan and scope of practice.

Distribution
  • Definition: movement of a drug from the blood to tissues and cells to reach the site of action.

  • Determinants: three main factors govern distribution:

    • Blood flow to tissues

    • Ability of the drug to exit capillary beds (capillary permeability)

    • Ability of the drug to enter cells

  • Special distribution considerations:

    • Blood–brain barrier (BBB): tight junctions protect CNS; crossing is harder; some drugs cross via cellular penetration or active transport; those crossing well often have specific properties.

    • Placenta: provides a barrier to drugs; P-glycoprotein transporters pump some drugs back to maternal blood; some drugs still cross to fetus, explaining fetal exposure and, in some cases, drug-related neonatal effects.

    • Albumin binding: many drugs bind to plasma albumin; if bound, they stay in the bloodstream and do not readily exit to tissues. Binding can be reversible; displacement or changes in albumin levels alter free drug concentration and effect.

  • Implications: distribution can affect drug levels at the site of action, potential toxicity, and interactions through displacement from albumin or competition for transporters.

Metabolism (Biotransformation)
  • Definition: body alters the drug’s chemical structure to modify activity and toxicity; most metabolism occurs in the liver.

  • Key enzyme system: hepatic cytochrome P450 family (CYP450) drives many metabolic reactions and drug interactions (the lecture references the liver’s enzyme system, commonly known as the CYP450 system).

  • Six possible metabolic outcomes (and their significance):

    • Accelerated excretion by increasing water solubility (most important clinical effect)

    • Inactivation of the drug (active drug becomes inactive)

    • Increased therapeutic action (drug is activated or made more potent)

    • Prodrugs (inactive or less active compound that is activated by metabolism)

    • Increased toxicity (bioactivation to toxic metabolites)

    • Decreased toxicity (reduced harmful effects)

  • First-pass effect (pre-systemic metabolism): orally administered drugs may be extensively metabolized in the liver before reaching systemic circulation, potentially abolishing activity; if this occurs, alternative routes (e.g., IV) may be used to bypass first-pass metabolism.

  • Additional factors affecting metabolism:

    • Age: infants have immature liver function; metabolism rates increase as liver matures (by about 1 year); elderly may have reduced metabolic capacity.

    • Drug–drug interactions: some drugs induce (activate) or inhibit liver enzymes, altering the metabolism rate of themselves or co-administered drugs.

Excretion
  • Definition: how drugs exit the body; primary route is via the kidneys, but other routes exist (breath, sweat, skin, and excretion via GI tract).

  • Renal excretion processes:

    • Glomerular filtration: drugs pass from blood through Bowman's capsule into urine (drugs must be small enough; mostly unbound in plasma).

    • Tubular reabsorption: some drugs are reabsorbed back into the bloodstream from the tubular filtrate.

    • Active tubular secretion (P-glycoprotein and other transporters): transporters pump drugs back into the urine for elimination.

  • Other excretion routes:

    • Breath (exhalation), sweat, and skin (sweat and dermal excretion)

  • Clinical relevance: accumulation and clearance rates affect drug levels; monitoring drug concentrations helps maintain efficacy while avoiding toxicity.

Drug concentrations and safety concepts
  • Drug concentration correlates with effect: higher drug levels generally produce greater effects up to a point.

  • Key concentration concepts:

    • Minimum effective concentration (MEC): the lowest concentration to achieve a therapeutic effect.

    • Therapeutic range: concentration range where the drug is effective with minimal harm; between MEC and toxic concentration.

    • Toxic concentration: concentration at which harm surpasses benefit.

  • Pharmacokinetic definitions:

    • Half-life (
      t_{1/2}
      ): time required for drug concentration to decrease by half.

    • Plateau / steady state: when drug intake sustains a level where fluctuations average out around a consistent concentration; achieved after repeated dosing aligned with half-life.

    • Loading dose: an initial larger dose to rapidly achieve the therapeutic concentration when a long time to reach plateau would otherwise delay effect.

Pharmacodynamics (drug effects on the body)

  • Definition: the study of how drugs exert biochemical and physiological effects; the relationship between dose and response.

  • Core concepts:

    • Dose–response relationship: as dose increases, response typically increases (graded response).

    • Maximal efficacy: the largest effect a drug can produce; not always the best choice (safety and necessity matter).

    • Potency: the amount of drug needed to produce a given effect; less drug required = higher potency (not necessarily better).

    • Receptors: drugs act via receptors (hormones, neurotransmitters, etc.) which must bind to produce effects; binding is reversible generally.

  • Receptor interactions and effects:

    • Receptors are like locks; drugs are keys; binding can turn on (agonist) or block (antagonist) receptor function.

    • Agonist: activates receptor to mimic normal body action (e.g., opioids). Antagonist: blocks receptor to prevent action (e.g., antihistamines, Narcan). Antagonists can prevent allergy symptoms by blocking histamine receptors.

    • Selectivity: the degree to which a drug acts on a given receptor relative to others; higher selectivity means fewer off-target effects.

  • Receptor theories:

    • Simple occupancy theory: response proportional to number of occupied receptors; does not explain potency differences well.

    • Modified occupancy theory: incorporates affinity (how strongly a drug binds) and intrinsic activity (ability to activate receptor) to explain varying potencies and efficacies.

    • Affinity: the strength of attraction between drug and receptor; higher affinity means a drug can achieve effect at lower concentrations (often linked to higher potency).

    • Intrinsic activity: the ability of a drug to activate a receptor once bound; higher intrinsic activity yields a stronger response (think of a light switch dimmer vs full on).

  • Receptors and dose concepts:

    • ED50 (average effective dose): the dose required to produce a therapeutic effect in 50% of the population; a starting point for dosing:

    • ED_{50}

    • LD50 (average lethal dose): the dose that is lethal in 50% of animals tested; used to calculate safety margins.

    • Therapeutic Index (TI): safety measure, defined as the ratio of LD50 to ED50:

    • A wider TI indicates a safer drug; a narrow TI requires careful dosing and monitoring.

  • Practical receptor concepts:

    • Multiple drugs can occupy receptors; selectivity reduces off-target effects but does not guarantee safety.

    • Agonists vs antagonists illustrated:

    • Agonist example: morphine activating opioid receptors to reduce pain.

    • Antagonist example: Narcan (naloxone) binding and blocking opioid receptors to reverse overdose.

    • Antihistamines act as antagonists at histamine receptors to prevent allergic symptoms when exposed to allergens.

Integration and clinical implications

  • Pharmacokinetics informs pharmacodynamics (what the body does to the drug vs what the drug does to the body).

  • Dosing decisions depend on: route of administration, absorption variability, distribution to target tissues, metabolism and excretion rates, and patient-specific factors (age, organ function, interactions).

  • First-pass effect can render an oral dose ineffective, driving route decisions (e.g., IV bypassing hepatic first-pass).

  • Drug interactions may alter metabolism (enzyme induction/inhibition) and distribution (e.g., competition for albumin binding).

  • Monitoring drug concentrations and patient response helps tailor therapy to maintain the therapeutic range and avoid toxicity

. Additionally, understanding the half-life of drugs is crucial for determining dosing intervals and achieving desired blood levels without causing adverse effects.

  • Half-life and plateau (conceptual):

    • t_{1/2} = \text{time required for concentration to decrease by 50%}

    • Plateau/steady state is reached when intake and elimination balance over dosing intervals.

  • First-pass effect (concept): orally administered drugs may be extensively metabolized in the liver before entering systemic circulation, potentially eliminating activity and necessitating alternative routes.

  • Depot/arc dosing (concept): depot injections provide slow, extended release to maintain therapeutic levels without frequent dosing.

End of pharmacokinetics and pharmacodynamics notes
  • Review focus areas for exams:

    • Remember the four pharmacokinetic processes and how they influence dosing decisions.

    • Understand absorption determinants and why routes differ in onset and intensity.

    • Recognize distribution factors (BBB, placenta, albumin binding).

    • Grasp metabolism and the role of CYP450; first-pass effects and age-related changes.

    • Know excretion pathways and renal handling (filtration, reabsorption, active secretion).

    • Distinguish pharmacodynamics concepts: dose–response, potency, efficacy, receptors, occupancy theory, and agonist/antagonist effects.

    • Use TI, ED50, and LD50 to think about safety margins and dosing strategies.